Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Anti-GD2 Chimeric Antigen Receptor-Expressing T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors

NCT03373097 is registered in ClinicalTrials.gov with Bambino Gesù Hospital and Research Institute as lead sponsor.

NCT NCT03373097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03373097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Anti-GD2 Chimeric Antigen Receptor-Expressing T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors
Lead sponsor
Bambino Gesù Hospital and Research Institute
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 5, 2018
Completion date
December 31, 2027
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, gd2-positive solid tumors, neuroblastoma, neuroblastoma recurrent, osteosarcoma, sarcoma